BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

524314

GUJTERC

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GUJARAT TERCE LABORATORIES LTD Share Price Update

As of the latest trading session, GUJARAT TERCE LABORATORIES LTD share price is currently at ₹ 54.26, which is down by ₹ -3.95 from its previous closing. Today, the stock has fluctuated between ₹ 53.00 and ₹ 61.50. Over the past year, GUJARAT TERCE LABORATORIES LTD has achieved a return of -11.90 %. In the last month alone, the return has been -9.75 %. Read More...

GUJARAT TERCE LABORATORIES LTD fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    40.30

  • P/E Ratio (TTM)

    14.63

  • Beta

    -0.12

  • Book Value / share

    11.94

  • Return on equity

    2.96%

  • EPS (TTM)

    3.98

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    1.01

info icon alternate text

GUJARAT TERCE LABORATORIES LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 12.68
Operating Expense 11.77
Net Profit 1.01
Net Profit Margin (%) 7.96
Earnings Per Share (EPS) 1.36
EBITDA 1.16
Effective Tax Rate (%) -3.06
Particulars SEP 2024 (Values in Cr)
Revenue 13.30
Operating Expense 11.86
Net Profit 1.48
Net Profit Margin (%) 11.12
Earnings Per Share (EPS) 2.00
EBITDA 1.73
Effective Tax Rate (%) 1.98
Particulars JUN 2024 (Values in Cr)
Revenue 11.89
Operating Expense 12.03
Net Profit -0.08
Net Profit Margin (%) -0.67
Earnings Per Share (EPS) -0.10
EBITDA 0.15
Effective Tax Rate (%) -14.28
Particulars MAR 2024 (Values in Cr)
Revenue 12.21
Operating Expense 11.45
Net Profit 0.54
Net Profit Margin (%) 4.42
Earnings Per Share (EPS) 0.73
EBITDA 1.08
Effective Tax Rate (%) 35.71
Particulars DEC 2023 (Values in Cr)
Revenue 13.02
Operating Expense 12.42
Net Profit 0.67
Net Profit Margin (%) 5.14
Earnings Per Share (EPS) 0.91
EBITDA 0.92
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 47.97
Operating Expense 47.76
Net Profit 0.24
Net Profit Margin (%) 0.50
Earnings Per Share (EPS) 0.33
EBITDA 1.59
Effective Tax Rate (%) 55.55
Particulars MAR 2023 (Values in Cr)
Revenue 46.78
Operating Expense 50.03
Net Profit -1.67
Net Profit Margin (%) -3.56
Earnings Per Share (EPS) -2.25
EBITDA -1.81
Effective Tax Rate (%) 42.21
Particulars MAR 2022 (Values in Cr)
Revenue 40.13
Operating Expense 39.69
Net Profit 0.87
Net Profit Margin (%) 2.16
Earnings Per Share (EPS) 1.18
EBITDA 1.43
Effective Tax Rate (%) -17.33
Particulars MAR 2021 (Values in Cr)
Revenue 25.18
Operating Expense 28.51
Net Profit -2.52
Net Profit Margin (%) -10.00
Earnings Per Share (EPS) -3.40
EBITDA -1.95
Effective Tax Rate (%) 0.39
Particulars MAR 2020 (Values in Cr)
Revenue 37.54
Operating Expense 37.39
Net Profit 0.28
Net Profit Margin (%) 0.74
Earnings Per Share (EPS) 0.37
EBITDA 0.97
Effective Tax Rate (%) 36.36
Particulars MAR 2024 (Values in Cr)
Book Value / Share 9.58
ROE % 2.96
ROCE % 7.17
Total Debt to Total Equity 0.80
EBITDA Margin 3.31
Particulars MAR 2023 (Values in Cr)
Book Value / Share 9.25
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.91
EBITDA Margin -3.87
Particulars MAR 2022 (Values in Cr)
Book Value / Share 11.50
ROE % 10.24
ROCE % 6.74
Total Debt to Total Equity 0.70
EBITDA Margin 3.54
Particulars MAR 2021 (Values in Cr)
Book Value / Share 10.33
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.39
EBITDA Margin -7.82
Particulars MAR 2020 (Values in Cr)
Book Value / Share 14.97
ROE % 2.55
ROCE % 5.04
Total Debt to Total Equity 0.15
EBITDA Margin 2.58
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 23.27
Total Liabilities 23.27
Total Equity 7.10
Share Outstanding 7420300
Price to Book Ratio 5.53
Return on Assets (%) 1.04
Return on Capital (%) 2.22
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2.02
Total Assets 28.52
Total Liabilities 28.52
Total Equity 6.86
Share Outstanding 7420300
Price to Book Ratio 1.80
Return on Assets (%) -5.85
Return on Capital (%) -11.83
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.50
Total Assets 27.39
Total Liabilities 27.39
Total Equity 8.53
Share Outstanding 7420300
Price to Book Ratio 2.27
Return on Assets (%) 3.18
Return on Capital (%) 5.74
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.28
Total Assets 21.87
Total Liabilities 21.87
Total Equity 7.66
Share Outstanding 7420300
Price to Book Ratio 0.67
Return on Assets (%) -11.52
Return on Capital (%) -20.33
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.04
Total Assets 22.50
Total Liabilities 22.50
Total Equity 11.11
Share Outstanding 7420300
Price to Book Ratio 0.42
Return on Assets (%) 1.22
Return on Capital (%) 2.02
Particulars MAR 2024 (Values in Cr)
Net Income 0.54
Cash from Operations 2.59
Cash from Investing -0.45
Cash from Financing -4.08
Net change in Cash -1.93
Free Cash Flow 2.67
Particulars MAR 2023 (Values in Cr)
Net Income -2.89
Cash from Operations 0.06
Cash from Investing 0.61
Cash from Financing -0.12
Net change in Cash 0.52
Free Cash Flow 0.12
Particulars MAR 2022 (Values in Cr)
Net Income 0.74
Cash from Operations -0.34
Cash from Investing -0.86
Cash from Financing 1.53
Net change in Cash 0.22
Free Cash Flow 1.77
Particulars MAR 2021 (Values in Cr)
Net Income -2.52
Cash from Operations -0.01
Cash from Investing -0.42
Cash from Financing 1.83
Net change in Cash 1.24
Free Cash Flow 0.48
Particulars MAR 2020 (Values in Cr)
Net Income 0.43
Cash from Operations -1.48
Cash from Investing -0.27
Cash from Financing 1.71
Net change in Cash -0.14
Free Cash Flow -1.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2904.45 57.61 29.41 49203.14 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

GUJARAT TERCE LABORATORIES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
54.26 -6.78 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 60.10
  • 26 Days 62.90
  • 10 Days 60.80
  • 50 Days 66.10
  • 12 Days 61.00
  • 100 Days 69.20
  • 20 Days 62.10
  • 200 Days 66.80
60.07 PIVOT

First Support

56.20

First Resistance

62.09

Second Support

54.18

Second Resistance

65.96

Third Support

50.31

Third Resistance

67.98

RSI

38.51

ADX

24.73

MACD

-1.93

Williams % R

-52.28

Commodity Channel Index (CCI)

-74.72

Date

2025-04-29

Week

2771.00

Same Day

2966.00

Month

2867.00

1 Year

-0.13

3 Year

0.17

Over 1 Month

-9.75%

down

Over 1 Year

-11.90%

down

Over 3 Months

-26.24%

down

Over 3 Years

22.84%

down

Over 6 Months

-27.15%

down

Over 5 Years

46.24%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

GUJARAT TERCE LABORATORIES LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
62.97%
Promoter Holdings
37.02%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Abundant Trade Link Private Limited 1075900.0 (14.5%) Shareholding of Promoter and Promoter Group
Aalap Natubhai Prajapati 980827.0 (13.22%) Shareholding of Promoter and Promoter Group
Natwarbhai Parsottam Prajapati 635817.0 (8.57%) Shareholding of Promoter and Promoter Group
Sagar Saxena 103252.0 (1.39%) Public Shareholding
Dheeraj Kumar Lohia 89799.0 (1.21%) Public Shareholding
Rishabh Negi 75000.0 (1.01%) Public Shareholding
Amritbhai P. Prajapati 31510.0 (0.42%) Shareholding of Promoter and Promoter Group
Shobhanaben Natvarbhai Prajapati 16173.0 (0.22%) Shareholding of Promoter and Promoter Group
Shachi Ravi Oza 7500.0 (0.1%) Shareholding of Promoter and Promoter Group
Prajapati Manjulaben S 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

GUJARAT TERCE LABORATORIES LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

GUJARAT TERCE LABORATORIES LTD Share Price

Gujarat Terce Laboratories Limited, incorporated in 1985, produces branded generic formulations for the domestic market. Over its more than three-decade business journey, the Company developed an extensive product basket comprising 50 brands covering multiple therapeutic areas which are marketed by its 180+ strong MR team across 13 Indian states. Headquartered in Ahmedabad, the Company has its fully automated facility at Chhatral, in Gandhinagar, Gujarat

By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing. In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange. In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat. As India heralded new leaps in the pharma sector to become a global force to reckon with by 2005, the Company closely followed the narrative with ferocious growth expanding presence in the domestic and international market.

The Company is an ISO 9001 certified, WHO-GMP compliant operating facility manufactures world-class formulations and healthcare products that feature in acute and chronic therapeutic areas. It engaged into manufacture and sale of pharmaceutical formulations and ayurvedic medicines in India and internationally. It offers products in the form of tablets, capsules, syrups, and injections. The installed capacity of the Company is 270 million tablets and 108 million capsules per annum.

The facility is ISO 9001 certified to manufacture world-class formulations and healthcare products for relief in acute and chronic therapeutic areas. The plant operates on the principles of Lean Manufacturing and Total Quality Management to reduces input costs and improve outcome efficiency. The plant is designed with dedicated HVAC system to prevent contamination and cross contamination. Terce has a separate facility to manufacture Cephalosporin antibiotics range.

The Company otherwise or hence maintains strict and controlled environment for manufacturing and adheres to Good Manufacturing Practices and Good Laboratory Practices to assure highest level of patient safety and outcome efficacy. It has well-defined Total Quality Management System in place to continuously optimize products and processes. Each process is thoroughly monitored and data is collected for analysis which helps in planning corrective and preventive strategies for quality control.

To serve the needs of patients and healthcare professionals, Company focus on early and rapid detection of diseases. Their team of scientists is supported by doctors, patients and marketing team in identifying pressing needs and developing solutions. It has capabilities of innovation across generic drugs to complex formulations, biosimilars and new molecular entity.

Parent organization Indian Private
NSE symbol [-]
Founded 1985
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Gujarat Terce Laboratories Ltd?

Answer Field

The share price of Gujarat Terce Laboratories Ltd for NSE is ₹ 0.00 and for BSE is ₹ 54.26.

What is the Market Cap of Gujarat Terce Laboratories Ltd?

Answer Field

The market cap of Gujarat Terce Laboratories Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 40.30 Cr. as of now.

What is the 52 Week High and Low of Gujarat Terce Laboratories Ltd?

Answer Field

The 52 Week High and Low of Gujarat Terce Laboratories Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 94.90 and ₹ 44.52.

How to Buy Gujarat Terce Laboratories Ltd share?

Answer Field

You can trade in Gujarat Terce Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Gujarat Terce Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -11.90%.

What is the Current Share Price of Gujarat Terce Laboratories Ltd?

Answer Field

Gujarat Terce Laboratories Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 54.26 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Gujarat Terce Laboratories Ltd Share?

Answer Field

The market cap of Gujarat Terce Laboratories Ltd for NSE ₹ 0.0 & for BSE ₹ 40.30 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Gujarat Terce Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Gujarat Terce Laboratories Ltd share is 14.63.

What is the PB ratio of Gujarat Terce Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Gujarat Terce Laboratories Ltd share is 11.94.

How to Buy Gujarat Terce Laboratories Ltd Share?

Answer Field

You can trade in Gujarat Terce Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Gujarat Terce Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Gujarat Terce Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Gujarat Terce Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|